Starton Therapeutics Files Patent Applications for the Use of CAR-T Cell Therapies in Combination with its Proprietary, Continuous Low-Dose Immunomodulatory Therapy, STAR-LLD, a formulation of Lenalidomide, for the Treatment of Blood Cancer

Author: Starton Therapeutics Inc.

Posted Date: